Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals, Inc. (ENTA) is a biotechnology leader focused on discovering novel small molecule drugs for viral infections and liver diseases. This dedicated news hub provides investors and industry observers with essential updates on the company's research advancements, regulatory milestones, and strategic initiatives.
Access authoritative coverage of ENTA's progress in developing direct-acting antiviral therapies and host-targeted approaches. The repository includes press releases related to clinical trial outcomes, partnership announcements with pharmaceutical collaborators, and updates on pipeline candidates targeting conditions like RSV and NASH.
Key updates feature developments in ENTA's chemistry-driven drug discovery platform, intellectual property achievements, and financial performance reports. All content is curated to support informed analysis of the company's position in the competitive antiviral therapeutics market.
Bookmark this page for streamlined access to verified ENTA developments. Check regularly for updates on FDA interactions, scientific publications, and partnership-driven commercialization efforts that shape the company's growth strategy.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported financial results for Q1 FY2025 ended December 31, 2024. Total revenue was $17.0 million, down from $18.0 million in Q1 FY2024, consisting of royalties from MAVYRET®/MAVIRET® sales. The company reported a net loss of $22.3 million ($1.05 per share), compared to a $33.4 million loss ($1.58 per share) in the prior year.
Research and development expenses decreased to $27.7 million from $36.4 million, while G&A expenses reduced to $12.8 million from $16.5 million. The company maintains a strong financial position with $216.7 million in cash and marketable securities, expected to fund operations into fiscal 2028.
Key developments include ongoing recruitment for the RSVHR Phase 2 study of zelicapavir, with topline data expected in Q3 2025, and advancement of immunology portfolio including KIT inhibitor EPS-1421 and STAT6 program development.
Enanta Pharmaceuticals (NASDAQ:ENTA) has announced that its President and CEO, Jay R. Luly, Ph.D., will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2024, at 8:15 a.m. PT in San Francisco, CA.
The clinical-stage biotechnology company, which focuses on developing small molecule drugs for virology and immunology indications, will provide a live webcast of the presentation through the "Events and Presentations" section on the "Investors" page of their website. The webcast recording will remain available for a minimum of 30 days following the presentation.
Enanta Pharmaceuticals (NASDAQ: ENTA) announced that the United States District Court of Massachusetts has ruled against them in a patent infringement lawsuit against Pfizer. The Court granted Pfizer's summary judgment motion, declaring Enanta's '953 Patent invalid. This patent was related to Pfizer's COVID-19 antiviral, Paxlovid.
The Court also denied Enanta's partial motion for summary judgment of infringement. Enanta plans to appeal the decision to the Court of Appeals for the Federal Circuit. Despite the ruling, the company maintains its commitment not to impede Paxlovid's production, sale, or distribution.
Enanta Pharmaceuticals announced positive topline results from its first-in-pediatrics Phase 2 study of zelicapavir for treating respiratory syncytial virus (RSV) in children aged 28 days to 36 months. The study demonstrated significant antiviral effects with a 1.4 log decline in viral load at Day 5 compared to placebo in Part 2. A prespecified analysis of patients treated within 3 days of symptom onset showed a 1.2 log decline in viral load.
The study involved 96 patients (70 receiving zelicapavir, 26 placebo) across two parts. Zelicapavir demonstrated a favorable safety profile with no adverse events leading to treatment discontinuation. The drug achieved target exposure levels across all age groups, with doses of 5 mg/kg for ages ≥28 days to <12 months and 7.5 mg/kg for ages ≥12 months to ≤36 months.
Enanta Pharmaceuticals (NASDAQ:ENTA) has announced an upcoming conference call and webcast scheduled for Monday, December 9 at 8:30 a.m. ET. The event will present topline results from RSVPEDs, a first-in-pediatrics Phase 2 study evaluating zelicapavir in children with respiratory syncytial virus (RSV). The study focused on both hospitalized and non-hospitalized children aged 28 days to 36 months.
The live webcast will be accessible through the company's website under the 'Events & Presentations' section in the investors area. Participants joining by phone are advised to register at least 15 minutes before the call to receive dial-in information. The webcast recording will remain available on Enanta's website for approximately 30 days after the event.
Enanta Pharmaceuticals reported financial results for Q4 and fiscal year 2024. Total revenue was $14.6M for Q4 and $67.6M for FY2024, down from $18.9M and $79.2M respectively in 2023, due to declining MAVYRET®/MAVIRET® sales. Net loss was $28.8M ($1.36 per share) in Q4 and $116.0M ($5.48 per share) for FY2024.
The company announced positive Phase 2a results for EDP-323 in RSV treatment and expanded its immunology portfolio with a new STAT6 inhibition program and EPS-1421 development candidate. Cash position stands at $248.2M, expected to fund operations into fiscal 2027.
Enanta Pharmaceuticals announced positive topline results from a Phase 2a human challenge study of EDP-323, a novel L-protein inhibitor for RSV treatment. The study demonstrated:
- 85-87% reduction in viral load AUC by qRT-PCR (p<0.0001)
- 97-98% reduction in infectious viral load AUC by viral culture (p<0.0001)
- 66-78% reduction of total clinical symptoms score AUC (p<0.0001)
EDP-323 showed a favorable safety profile and pharmacokinetics supporting once-daily dosing. The drug achieved rapid and sustained antiviral effects, with results among the strongest reported in an RSV challenge study. Enanta aims to develop EDP-323 as a safe, effective oral treatment for RSV, addressing a substantial unmet medical need.
Enanta Pharmaceuticals (NASDAQ:ENTA), a clinical-stage biotechnology company, has announced its participation in three upcoming investor conferences in September 2024. The company's management will be involved in fireside chats at the following events:
- Baird 2024 Global Healthcare Conference on September 10 at 2:35 p.m. ET
- H.C. Wainwright 26th Annual Global Investment Conference on September 11 at 10:00 a.m. ET
- 2024 Cantor Global Healthcare Conference on September 17 at 10:55 a.m. ET
Live webcasts of these events will be available on the 'Events and Presentations' section of Enanta's website. Replays will be archived for at least 30 days after the presentations.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported financial results for its fiscal third quarter ended June 30, 2024. Total revenue was $18.0 million, consisting of royalty revenue from AbbVie's HCV regimen MAVYRET/MAVIRET. The company reported a net loss of $22.7 million, or $1.07 per diluted share. Enanta's cash and marketable securities totaled $272.6 million as of June 30, 2024.
Key highlights include:
- Completion of enrollment for RSVPEDs, a Phase 2 study of zelicapavir in pediatric RSV patients
- Completion of EDP-323 Phase 2a Challenge Study in RSV
- Advancement of KIT inhibitors for chronic spontaneous urticaria
- Expected cash runway through Q3 2027
Enanta Pharmaceuticals (NASDAQ: ENTA), a clinical-stage biotechnology firm specializing in small molecule drugs for virology and immunology, has announced its participation at the Jefferies Global Healthcare Conference. The event will feature a fireside chat with President and CEO Jay R. Luly, Ph.D., and Chief Product Strategy Officer Tara L. Kieffer, Ph.D. The session is set for June 5, 2024, at 7:30 a.m. ET in New York, NY. A live webcast of the discussion will be available on Enanta's website, with a replay accessible for at least 30 days post-event.
FAQ
What is the current stock price of Enanta Pharmaceuticals (ENTA)?
What is the market cap of Enanta Pharmaceuticals (ENTA)?
